Research Type: Assessment

Treatments of Interest: Vedolizumab (Entyvio®, Takeda) Infliximab (Remicade®, Janssen) Infliximab-dyyb (Inflectra®, Pfizer) Infliximab-abda (Renflexis®, Merck) Adalimumab (Humira®, AbbVie) Golimumab (Simponi®, Janssen) Tofacitinib (Xeljanz®, Pfizer) Ustekinumab (Stelara®, Janssen) Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that affects the mucosa, the innermost lining of the intestinal wall in the large bowel (i.e., the colon […]

Interventions of Interest: Tezacaftor/ivacaftor (SymdekoTM, Vertex Pharmaceuticals) Lumacaftor/ivacaftor (Orkambi®, Vertex Pharmaceuticals) Ivacaftor (Kalydeco®, Vertex Pharmaceuticals) Elexacaftor/tezacaftor/ivacaftor (Trikafta®, Vertex Pharmaceuticals) Cystic fibrosis is an autosomal recessive condition caused by mutations in the CFTR gene. It is relatively rare, occurring in approximately 1 in 2,500 to 3,000 livebirths, but is the most common, lethal genetic disease in […]